Valo Therapeutics and ImmunoScape Collaboration Identifies Immunogenic Peptides to Develop Pan Coronavirus Vaccine
Helsinki, Finland, 9 March 2021: Valo Therapeutics Limited (Valo Tx), the developer of novel and adaptable immunotherapy platforms for cancer and infectious diseases, today announced the completion of a successful collaboration with the biotechnology company ImmunoScape (Singapore and San Diego) to identify immunogenic peptides for the development of a pan Coronavirus vaccine.
